Order Today at amga.org
This report includes:
• Operational area sta;ng and salary information
• P&L summaries by organizational class
• Financial summaries by specialty
• Accounts receivable analysis
Data is delineated in a variety of ways:
• Health systems vs. private physician practices
• Group size and region
• Level of capitation
• Per physician FTE, per work RVU and
per square foot
The latest operations
and finance data for
Get a clear and
complete picture of the
market with operational
and financial data from
follow-up action within three months of a positive screening
(see Figure 1):
+ 35% had a diagnosis and/or prescription for an
anti-diabetes medication (Figure 1: blue bars).
+ 30% had neither diagnosis nor prescription but had a
subsequent negative diabetes test result (Figure 1: teal
and green bars).
+ The remaining 35% had neither diagnosis nor prescription, and either re-tested positive for diabetes or had no
follow-up screening (Figure 1: light and dark purple bars).
F By 12 months, 83% of all patients received appropriate
F Among the 7% of patients with an HbA1c screening > 8.0,
92% and 96% had appropriate follow-up within three and
12 months, respectively.
F Most initial prescriptions were for metformin (84%), with
variation in use of second- or third-line diabetes medications:
sulfonylurea, 1%–12%; inhibitors of dipeptidyl peptidase 4
(DPP- 4), 0%–10%; sodium-glucose cotransporter- 2 (SGLT2)
inhibitors, 0%–10%; glucagon-like peptide 1 receptor agonist (GLP- 1 RA), 0%–3%; and insulin, 1%–12%.
F Within a year of a positive diabetes screen, most patients
received appropriate action. Those with higher laboratory
values were more likely to receive appropriate action sooner.
Among those with prescriptions, most were for metformin.
The proportion of patients with appropriate action, time to
action, and type of action (e.g., use of second- and third-line agents) all varied considerably across HCOs.
While most patients who screen positive for diabetes receive
appropriate follow-up within 12 months (83%), results vary
across health systems (76%–91%). In addition, only 56% of
eligible patients are screened in the first place. Healthcare
systems should review their own screening and follow-up
data to identify gaps in care at their own organizations.
AMGA Analytics Team who contributed to this study: Cori R.
Rattelman, M.S.; Nikita Stempniewicz, M.Sc.; and Elizabeth L.
Ciemins, Ph.D., M.P.H.
1. Centers for Disease Control and Prevention. 2018. Diabetes Quick
Facts. Accessed February 4, 2019 at cdc.gov/diabetes/basics/
2. American Diabetes Association. 2018. Standards of Care in
Diabetes, 2018. Diabetes Care, 41(Suppl. 1): 1–150.
3. N. Stempniewicz, J.K. Cuddeback, C.R. Rattelman, and E.L.
Ciemins. 2018. Screening Patients for Diabetes in a Large,
National Clinical Database. Diabetes, 67(Suppl. 1). See abstract
accessed February 4, 2019 at diabetes.diabetesjournals.org/